Clinical Trial Update: Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study evaluating CPI-613 (devimistat) given twice weekly for three consecutive weeks in patients with advanced hematologic malignancies to assess safety…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• CPI-613 (devimistat) (devimistat)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Advanced Hematologic Malignancies | Phase 1 | Status: COMPLETED